FDA accepts Karyopharm application for expanded use of selinexor

Under Priority Review status, the FDA accepts Karyopharm Therapeutics’ (NASDAQ:KPTI) supplemental marketing application seeking approval to use Xpovio (selinexor) to treat adults with relapsed/refractory diffuse large B-cell lymphoma who have received at least two prior therapies.

The agency’s action date is June 23.

The FDA approved the nuclear export inhibitor in July 2019 for multiple myeloma.

https://seekingalpha.com/news/3543202-fda-accepts-karyopharm-application-for-expanded-use-of-selinexor